Latest news in cancer
Fruquintinib is approved by the USFDA in refractory metastatic colorectal cancer
The Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) on November 8, 2023, for adult patients with metastatic...
Enzalutamide is approved by the USFDA for non-metastatic castration-sensitive prostate cancer with biochemical recurrence
The FDA has authorized enzalutamide for the treatment of non-metastatic castration-sensitive prostate cancer in cases of biochemical recurrence. The Food and...
Capivasertib with fulvestrant is approved by the USFDA for breast cancer treatment
Capivasertib (Truqap, AstraZeneca Pharmaceuticals) in combination with fulvestrant was approved by the Food and Drug Administration on November 16, 2023, for...
Pembrolizumab with chemotherapy is approved by the USFDA for HER2-negative gastric or gastroesophageal junction adenocarcinoma
The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with fluoropyrimidine- and platinum-containing chemotherapy on...
Repotrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer
The Food and Drug Administration authorized repotrectinib (Augtyro, Bristol-Myers Squibb Company) for locally advanced or metastatic ROS1-positive non-small...
Fruquintinib is approved by the USFDA in refractory metastatic colorectal cancer
The Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) on November 8, 2023, for adult patients with metastatic...
FDA revises pembrolizumab’s indication for gastric cancer
The Food and Drug Administration updated the approved use of pembrolizumab (Keytruda, Merck) in combination with trastuzumab, fluoropyrimidine, and...
Pembrolizumab with chemotherapy is approved by the USFDA for biliary tract cancer
On October 31, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) to be used with gemcitabine and cisplatin to treat biliary tract...
Toripalimab-tpzi is approved by the FDA for nasopharyngeal carcinoma
In October 2023, the FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine as the first-line treatment for people...
Stem Cell Therapy for Diabetes: A Promising Treatment Approach
March 2024: Stem cell therapy has emerged as a promising treatment option for diabetes mellitus, potentially addressing the obstacles that patients encounter....
Revolutionizing Multiple Myeloma Treatment through CAR T-Cell Therapy in China
Feb 2024: China’s pioneering efforts in creating breakthrough cancer therapeutics have gained traction with the introduction of chimeric antigen receptor...
Mesenchymal stem cells (MSC) and platelet-rich plasma (PRP) therapy in the treatment of knee osteoarthritis
Feb 2024: Mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) therapy have shown potential in treating knee osteoarthritis (KOA) in China. A...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.